Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 +/- PD-1 Inhibitor in TNBC
NCT06492005Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Jul 2024
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bulumtatug fuvedotin in triple-negative breast cancer (TNBC), sponsored by Mabwell. Started Jul 2024; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06492005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492005.